All the Active Ingredient Drugs
Anti-VEFG, Monoclonal Antibody. Ranibizumab 10 mg/ml. VIAL: 1 x 0.23 ml.
PFS: 1 x 0.165 ml. Initial: 0.5 mg given as a single intravitreal inj. This correspond. to an inj. volume of 0.05 ml. The interval between two doses inj. into the same eye should not be shorter than 1 m. See lit.
Preterm infants: 0.2 mg given as an intravitreal inj. This correspond. to an inj. volume of 0.02 ml. In preterm infants tmt. of ROP is initiat. with a single inj. per eye and may be given bilaterally on the same day. In total, up to three inj. per eye may be admin. within 6 mnths. of tmt. init. if there are signs of dis. activity.
The tmt. of pts. with neovascular (wet) age-related macular degenerat. (AMD).
The tmt. of adult pts. with visual impair. due to diabet. macular edema (DME).
The tmt. of visual impair. due to macular edema second. to retinal vein occlus. (RVO).
The tmt. of visual impair. due to choroidal neovascularization (CNV) second. to pathologic myopia (PM).
Indicated in preterm infants for: Tmt. of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) dis.
C/I: Hypersens., Active/suspect. oc./perioc. infects., Severe intraoc. inflamm.
Anti-VEFG, Monoclonal Antibody. Ranibizumab 10 mg/ml. Sol. for inject.: 1 X 0.23 ml /vial
Dose in adults : 0.5 mg given as a single intravitreal inject. This corresponds to an inject. vol. of 0.05 ml. Interval between 2 doses injected into the same eye should be at least 4 weeks. See lit.
Pts. with neovascular (wet) age-related macular degeneration (AMD)
Adult pts. with visual impairment due to diabetic macular oedema (DME)
Visual impairment due to macular oedema second. to retinal vein occlusion (RVO)
Visual impairment due to choroidal neovascularization (CNV)
Proliferative diabetic retinopathy (PDR)
C/I: Hypersens.
Active or suspected ocular or periocular infections.
Active severe intraocular inflammation.
